Compare Cytokinetics Inc (CYTK) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Tidewater Inc — how do they compare? Cytokinetics Inc trades at $82.27 (market cap $11.12B), while Tidewater Inc trades at $72.87 (market cap $3.68B). The key difference: Cytokinetics Inc is far larger — about 3× Tidewater Inc's market cap, and Cytokinetics Inc is trading nearer its 52-week high, Tidewater Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | TDW | |
|---|---|---|
Market Cap | $11.12B | $3.68B |
Sector | Technology | Utilities |
52-Week High | $87.26 | $91.12 |
52-Week Low | $33.23 | $46.32 |
Enterprise Value | $11.59B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Tidewater (TDW) trades at $74.35, up 1.34% today, with a bullish technical outlook driven by moving averages and ADX signals. Recent earnings show volatility with Q1 2026 missing estimates at $0.12 versus $0.75 expected, though Q3 2025 beat expectations. The company maintains strong profitability with a 22.16% net margin and robust cash flow from operations of $379.11M in 2025. News highlights include FTAI Infrastructure's acquisition of Tidewater Logistics in June 2026, potentially impacting operations.
The stock presents a mixed outlook; valuation metrics like a P/E of 12.47 suggest potential undervaluation, but earnings misses and a 'Hold' analyst consensus (61.54% hold ratings) indicate caution. Key risks include execution challenges in offshore support services and oil market volatility. Upside hinges on reversing recent earnings underperformance and capitalizing on industry acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
